China SXT Pharmaceuticals, Inc. (SXTC) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SXTC Revenue Growth
SXTC Revenue Analysis (2016–2025)
As of May 8, 2026, China SXT Pharmaceuticals, Inc. (SXTC) generated trailing twelve-month (TTM) revenue of $1.7 million, reflecting moderate decline in growth of -7.8% year-over-year. The most recent quarter (Q4 2025) recorded $455,709 in revenue, up 0.0% sequentially.
Looking at the longer-term picture, SXTC's 5-year compound annual growth rate (CAGR) stands at -19.5%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $7.0 million in 2018.
When compared to Healthcare sector peers including SBFM (+19.2% YoY), TCMD (+17.2% YoY), and CODA (+33.2% YoY), SXTC has underperformed the peer group in terms of revenue growth. Compare SXTC vs SBFM →
SXTC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SXTCCurrent | $2M | -7.8% | -19.5% | -154.0% | |
 SBFM | $35M | +19.2% | +340.1% | -16.7% | |
 TCMD | $330M | +17.2% | +12.0% | 8.9% | |
 CODA | $27M | +33.2% | +5.8% | 17.1% | |
 CCRN | $1.1B | -39.5% | +4.7% | -0.3% |
SXTC Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.7M | -9.7% | $367K | 21.1% | $-2,680,479 | -154.0% |
| 2024 | $1.9M | -2.2% | $554K | 28.7% | $-2,515,217 | -130.4% |
| 2023 | $2.0M | -24.2% | $426K | 21.6% | $-5,607,509 | -284.4% |
| 2022 | $2.6M | -45.5% | $1.3M | 48.1% | $-5,189,673 | -199.4% |
| 2021 | $4.8M | -7.5% | $2.8M | 59.4% | $-2,197,076 | -46.0% |
| 2020 | $5.2M | -26.4% | $2.7M | 52.4% | $4.3M | 83.0% |
| 2019 | $7.0M | -0.1% | $4.6M | 65.8% | $1.8M | 25.2% |
| 2018 | $7.0M | +43.8% | $3.4M | 48.5% | $1.6M | 23.3% |
| 2017 | $4.9M | +31.3% | $2.3M | 47.4% | $1.6M | 32.8% |
| 2016 | $3.7M | - | $794K | 21.4% | $209K | 5.6% |
See SXTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SXTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SXTC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSXTC — Frequently Asked Questions
Quick answers to the most common questions about buying SXTC stock.
Is SXTC's revenue growth accelerating or slowing?
SXTC revenue declined -7.8% year-over-year, contrasting with the 5-year CAGR of -19.5%. TTM revenue fell to $2M. This reverses the prior growth trend.
What is SXTC's long-term revenue growth rate?
China SXT Pharmaceuticals, Inc.'s 5-year revenue CAGR of -19.5% reflects the variable expansion pattern. Current YoY growth of -7.8% is below this long-term average.
How is SXTC's revenue distributed by segment?
SXTC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.